Medical Oncology, Santa Chiara Hospital, Largo Medaglie d'Oro 1, 38122, Trento, Italy.
Future Oncol. 2021 Feb;17(5):597-609. doi: 10.2217/fon-2020-0701. Epub 2021 Jan 6.
The brain is one of the most frequent sites of metastases in lung cancer patients, whose prognosis is related to the histological, biomolecular and clinical features of the disease. Over the years, the survival has improved significantly with the introduction of immune checkpoint inhibitors (ICIs), but there are limited data concerning their efficacy in patients with brain metastases. The aim of this review is to describe the biological mechanisms supporting the use of immunotherapy for brain metastases and the outcomes experienced by lung cancer patients with brain involvement enrolled in Phase III registration trials of ICIs. We also review retrospective data on ICIs alone or combined with brain radiotherapy, and indicate future directions for preclinical and clinical research.
大脑是肺癌患者转移的最常见部位之一，其预后与疾病的组织学、生物分子和临床特征有关。随着免疫检查点抑制剂（ICI）的引入，近年来患者的生存率显著提高，但关于它们在脑转移患者中的疗效的数据有限。本综述的目的是描述支持免疫疗法治疗脑转移的生物学机制，以及在 ICI 的 III 期注册试验中入组的脑转移肺癌患者的治疗结果。我们还回顾了 ICI 单独或联合脑放疗的回顾性数据，并指出了临床前和临床研究的未来方向。
